Recent work on breast cancer patients has suggested that MMP-2 negativity may be linked with a favourable prognosis in node-negative breast carcinoma (Hirvonen et al, 2003) and that high activity levels of plasma MMP-9 in breast cancer patients are associated with a worst overall survival rate (Ranuncolo et al, 2003). The gene discussed is MMP9; the disease is breast cancer.